F.ChenH.HanZ
Signing 57 new customers22 of them in Q4 aloneunderscores the industrys accelerating shift toward intelligent, automated collections and credit risk management
May 27, 2026, 09:00 ET Phase 3 REIMAGINE 13 trial results across a range of type 2 diabetes patient groups offer further insight into CagriSema, a novel amylin RA and a GLP-1 RA in a fixed-dose combination 1 Mid-stage trial data for investigational zenagamtide explore the safety and efficacy of the injectable formulation of the novel GLP-1/amylin-based treatment 2 New Ozempic and Wegovy data provide further evidence of semaglutide's strong cardiometabolic profile PLAINSBORO, NJ and BAGSVRD, Denmark, May 27, 2026 /PRNewswire/ -- Novo Nordisk today announced that new data from its cardiometabolic portfolio and pipeline will be showcased at the upcoming 2026 Scientific Sessions of the American Diabetes Association (ADA), taking place in New Orleans, June 58, 2026
Safety Considerations and Contraindications for Wegovy in Perimenopause Wegovy is generally well-tolerated , but like all medications, it carries potential adverse effects and specific considerations that require careful assessment, particularly in perimenopausal women who may have additional health concerns
Naturally occurring GLP-1R peptide agonists share a conserved N-terminal sequence with GLP-1, including oxyntomodulin and the first FDA approved GLP-1R agonist, exendin-4 (Fig
The statistical significance level was set up as p 0.40: large affect
